Literature DB >> 22002724

TGFβ-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa.

Julia Knaup1, Christina Gruber, Barbara Krammer, Verena Ziegler, Johann Bauer, Thomas Verwanger.   

Abstract

BACKGROUND: Recessive dystrophic epidermolysis bullosa (RDEB) is a hereditary skin disorder characterized by mechanical fragility of the skin, resulting in blistering and chronic wounds. The causative mutations lie in the COL7A1 gene. Patients suffering from RDEB have a high risk to develop aggressive, rapidly metastasizing squamous cell carcinomas (SCCs). Cutaneous RDEB SCCs develop preferentially in long-term skin wounds or cutaneous scars. Albeit being well differentiated, they show a more aggressive behavior than UV-induced SCCs. These findings suggest other contributing factors in SCC tumorigenesis in RDEB.
OBJECTIVE: To analyze factors contributing to RDEB tumorigenesis, we conducted a comprehensive gene expression study comparing a non-malignant RDEB (RDEB-CL) to a RDEB SCC cell line (SCCRDEB4) to achieve an overview on the changes of the gene expression levels in RDEB related skin cancer.
METHODS: We applied cDNA arrays comprising 9738 human expressed sequence tags (EST) with various functions. Selected results were verified by Real-time RT PCR.
RESULTS: Large-scale gene expression analysis revealed changes in the expression level of transforming growth factor β1 (TGFβ1) and several genes under the control of TGFβ for RDEB and SCCRDEB4 cell lines. Even untransformed RDEB keratinocytes show elevated levels of TGFβ1.
CONCLUSION: Our findings demonstrate a prominent role of TGFβ-signaling in RDEB-related skin cancer. Once activated, TGFβ signaling either in response to wounding or in order to influence type VII collagen expression levels could facilitate cancer development and progression. Moreover, TGFβ signaling might also represent a potentially useful therapeutic target in this disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002724      PMCID: PMC4605790          DOI: 10.3233/ACP-2011-0039

Source DB:  PubMed          Journal:  Anal Cell Pathol (Amst)        ISSN: 2210-7177            Impact factor:   2.916


  13 in total

Review 1.  Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa.

Authors:  Michael Vanden Oever; Kirk Twaroski; Mark J Osborn; John E Wagner; Jakub Tolar
Journal:  Pediatr Res       Date:  2017-11-01       Impact factor: 3.756

2.  Cutaneous squamous cell carcinoma developing from recessive dystrophic epidermolysis bullosa: a case report and an immunohistochemical study.

Authors:  Akira Tsukada; Taku Fujimura; Sadanori Furudate; Yumi Kambayashi; Yukikazu Numata; Takahiro Haga; Akira Hashimoto; Setsuya Aiba
Journal:  Case Rep Dermatol       Date:  2012-09-19

3.  Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa.

Authors:  Christopher Perdoni; John A McGrath; Jakub Tolar
Journal:  Stem Cell Res Ther       Date:  2014-11-06       Impact factor: 6.832

4.  Fibroblast and keratinocyte gene expression following exposure to extracts of neem plant (Azadirachta indica).

Authors:  Takao Someya; Katsura Sano; Kotaro Hara; Yoshimasa Sagane; Toshihiro Watanabe; R G S Wijesekara
Journal:  Data Brief       Date:  2017-12-20

5.  Fibroblast and keratinocyte gene expression following exposure to the extracts of holy basil plant (Ocimum tenuiflorum), malabar nut plant (Justicia adhatoda), and emblic myrobalan plant (Phyllanthus emblica).

Authors:  Takao Someya; Katsura Sano; Kotaro Hara; Yoshimasa Sagane; Toshihiro Watanabe; R G S Wijesekara
Journal:  Data Brief       Date:  2018-01-04

6.  Identification of novel enriched recurrent chimeric COL7A1-UCN2 in human laryngeal cancer samples using deep sequencing.

Authors:  Ye Tao; Neil Gross; Xiaojiao Fan; Jianming Yang; Maikun Teng; Xu Li; Guojun Li; Yang Zhang; Zhigang Huang
Journal:  BMC Cancer       Date:  2018-03-02       Impact factor: 4.430

7.  Exposed CendR Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa.

Authors:  Toini Pemmari; Larisa Ivanova; Ulrike May; Prakash Lingasamy; Allan Tobi; Anja Pasternack; Stuart Prince; Olli Ritvos; Shreya Makkapati; Tambet Teesalu; Mitchell S Cairo; Tero A H Järvinen; Yanling Liao
Journal:  Mol Ther       Date:  2020-05-20       Impact factor: 11.454

8.  A cancer stem cell-like phenotype is associated with miR-10b expression in aggressive squamous cell carcinomas.

Authors:  Monika Wimmer; Roland Zauner; Michael Ablinger; Josefina Piñón-Hofbauer; Christina Guttmann-Gruber; Manuela Reisenberger; Thomas Lettner; Norbert Niklas; Johannes Proell; Mila Sajinovic; Paul De Souza; Stefan Hainzl; Thomas Kocher; Eva M Murauer; Johann W Bauer; Dirk Strunk; Julia Reichelt; Albert Sleiman Mellick; Verena Wally
Journal:  Cell Commun Signal       Date:  2020-04-10       Impact factor: 5.712

9.  In vitro analysis of photosensitizer accumulation for assessment of applicability of fluorescence diagnosis of squamous cell carcinoma of epidermolysis bullosa patients.

Authors:  Patrick Larisch; Thomas Verwanger; Kamil Onder; Barbara Krammer
Journal:  Biomed Res Int       Date:  2012-12-30       Impact factor: 3.411

Review 10.  Interplay between Cell-Surface Receptors and Extracellular Matrix in Skin.

Authors:  Svenja Kleiser; Alexander Nyström
Journal:  Biomolecules       Date:  2020-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.